Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. - Wikidata - wikimedia - TriplyDB

Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.

Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.

http://www.wikidata.org/entity/Q30432032

about

Muscle-invasive urothelial bladder cancer: an update on systemic therapy Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin Clinical Translation of Nanomedicine.Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial Periostin suppresses in vivo invasiveness via PDK1/Akt/mTOR signaling pathway in a mouse orthotopic model of bladder cancer A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion Histopathological assessment of inflammation and expression of inflammatory markers in patients with ketamine-induced cystitis.Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.Personalized therapy for urothelial cancer: review of the clinical evidence.Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease.GOLPH3 is a potential therapeutic target and a prognostic indicator of poor survival in bladder cancer treated by cystectomy.The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion The effect of gartanin, a naturally occurring xanthone in mangosteen juice, on the mTOR pathway, autophagy, apoptosis, and the growth of human urinary bladder cancer cell lines AMPKα Is Suppressed in Bladder Cancer through Macrophage-Mediated Mechanisms.Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin.Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.Novel molecular targets for the therapy of urothelial carcinoma.New treatments for bladder cancer: when will we make progress?Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.mTOR inhibitors in urinary bladder cancer.Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling.The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients.Suppression of HSP27 increases the anti‑tumor effects of quercetin in human leukemia U937 cells Metformin induces degradation of mTOR protein in breast cancer cells.Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

P2860

Q26775780-16B8EC06-E12C-48D1-BA49-C90CCE222407 Q27015640-E6519C28-F70B-479C-961E-6A76FAE1102D Q30355939-D8D1FC53-7DA2-44AC-ADEF-C8C26F9415D5 Q33410691-E690735A-2D05-41C7-88C9-0B0024CCC491 Q33751028-9355355D-F815-458C-8FA5-B4A3607204D9 Q33886553-DDB2951B-0501-4E0D-A6E2-4F5945816851 Q33889872-D39C05A2-62D6-4713-8950-8722DB8848D9 Q35060424-42CCB33B-DE67-4A9B-AD8B-638533B29387 Q35110940-178556F1-3345-4261-8AD4-CBBF0567548D Q35157985-EE50078A-E621-4615-B5CD-D2225C7DB70C Q36027204-0D913A86-6804-466D-A8AD-7849968FD59B Q36061127-C0BD2386-306F-4887-A75D-0EB2994514E8 Q36062762-C36A5263-A7C0-43D1-966A-7E685927A0AD Q36087194-1F150F36-1749-4917-A8D8-19CD1FF45CC3 Q36544805-3428C2C9-539D-4558-B103-15529D899A92 Q36765779-A41A5C77-7FF8-4221-BEB1-EF9BD9B04D16 Q36820882-FBEE5E10-E9B6-4845-940F-6015D4739DAF Q36885716-F7F019B0-E093-47CB-99D7-22479F0448EE Q36899375-D0FC10BA-7C2B-44EF-9677-2B77C1F87EEE Q37482647-E40D655D-B6E9-44F7-9D9D-7571A8A59728 Q37730668-9A8DD550-8637-4AE9-9BD0-A7EFDA04F653 Q37775890-2D81B6F7-C40F-4CAF-B080-132436F9F2BA Q37871915-FD20D372-EDB2-4784-AF55-43F21A02D455 Q38003195-76514783-8E19-47B4-BB57-D6E5D21CBE34 Q38177753-40A26D72-29BB-443E-A254-2E0470721DC1 Q38312045-AB53C9E1-D054-4B4F-88DA-4F823B2DA355 Q38735342-69B065AB-27B9-44C1-9246-4FDDEDE79F7A Q38737064-32CCFB35-A6D5-4492-9BD0-1C38DA3F0813 Q38807880-021C3336-E230-466B-9464-A46355FE73A7 Q39042097-20640274-3E69-461D-A650-BCD2DF3EA95C Q40510800-83458072-21BF-4EF7-AA5E-DC7F65620FD4 Q41913207-4B4B1055-7292-408D-B368-352A4670E46D Q42068149-B34E1AD8-5375-4747-AE99-8E6073E7E915 Q42364561-E1C09C4B-1588-442F-883B-DF1D0AE7F00D Q47140976-A60E551A-5454-4AAC-A821-20E7E7F58AF9 Q48839946-12F25080-9CDB-4581-8649-06DE43C34377 Q54285690-69532F83-ACDD-4700-BF71-391EF6BEFE59

P2860

Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.

http://www.wikidata.org/entity/Q30432032

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Mammalian target of rapamycin ...... rowth in urothelial carcinoma.

@ast

Mammalian target of rapamycin ...... rowth in urothelial carcinoma.

@en

type

label

Mammalian target of rapamycin ...... rowth in urothelial carcinoma.

@ast

Mammalian target of rapamycin ...... rowth in urothelial carcinoma.

@en

prefLabel

Mammalian target of rapamycin ...... rowth in urothelial carcinoma.

@ast

Mammalian target of rapamycin ...... rowth in urothelial carcinoma.

@en

P1433

Q30432032-D32F8401-D66B-4721-815F-38AAD406A942

P1476

Q30432032-E6EF13A8-AFB2-4580-9F52-F74CB15BD000

P2093

Q30432032-04FA2C0C-B77F-402F-B15C-30EB75D91968

Q30432032-055C10A7-40D7-499D-ADDD-E406DA76A7AE

Q30432032-2E1B3B8B-704C-4A8C-9844-1A9A4F75E7B3

Q30432032-32E829B3-A882-4305-999C-2A3C76A68B47

Q30432032-62659494-C790-4837-BAC5-CD7B6F7EBA39

Q30432032-83CB5AB2-8C4F-421C-88E4-FFDFC816BCA9

Q30432032-887145C9-5268-4ECF-B17C-EFF30B5EEB44

Q30432032-CC002E47-0457-47F3-AA6E-E0BCB4323B91

Q30432032-D7EC4603-019B-42B6-A452-57138BAB1267

Q30432032-D9794025-F814-407B-B9E2-35382F140932

P2860

Q30432032-01F1F679-749D-4CB1-9F46-35E5B2979605

Q30432032-1113CCBF-53FD-43AD-B3A9-D957E3A793BE

Q30432032-1F02729A-8B51-4AA5-9F5E-87A3DF5AFAD3

Q30432032-2866679D-177B-4006-871A-A6DC5108C498

Q30432032-2A070AD2-2BE0-49AF-907E-0646EB08F477

Q30432032-2C652122-2179-4E2B-9439-294B6CE25662

Q30432032-337FD80A-AE13-4FEA-9966-66B126C4A192

Q30432032-3B6A2561-1AC6-417A-A585-4871626B6AD7

Q30432032-3BFFAE5A-ADA1-47FD-BFD2-D008F474A74B

Q30432032-42693566-7708-47F5-9FA2-98FB80891719

P304

Q30432032-F7902D65-DF4B-47F4-8750-A0DAA5B6D600

P31

Q30432032-5E1A3BEB-A5B5-4866-B8E7-007D99F49195

P356

Q30432032-AE2D52AB-4D4F-4780-9300-F72FCC420474

P407

Q30432032-2886F9F3-A79D-4CFB-9960-1965DECD1A67

P433

Q30432032-961024A8-4764-4C6A-B559-BCCB1881EF10

P478

Q30432032-845AAB73-2BC7-42DE-9A3E-2B7178FB2D6E

P50

Q30432032-9AD52408-32FE-4BDC-AA11-0E42F4D54591

P577

Q30432032-A2D0C16A-4470-4415-A996-246B73C818A7

P5875

Q30432032-F5CB9D5E-610F-4425-9AE2-2A4E8A2DF40E

P698

Q30432032-F932FD5A-82A5-4F03-AD05-FCEE278F625E

P932

Q30432032-34E93F16-9CC6-4508-AD0E-C09E98DDE5BD

P356

AJPATH.2010.090872

P1433

The American Journal of Pathology

P1476

Mammalian target of rapamycin ...... rowth in urothelial carcinoma.

@en

P2093

Angelo De Marzo

http://www.w3.org/2001/XMLSchema#string

Christina B Ching

http://www.w3.org/2001/XMLSchema#string

Dan Theodorescu

http://www.w3.org/2001/XMLSchema#string

Donna E Hansel

http://www.w3.org/2001/XMLSchema#string

Eric D Hsi

http://www.w3.org/2001/XMLSchema#string

Eric Platt

http://www.w3.org/2001/XMLSchema#string

Jessica L Hicks

http://www.w3.org/2001/XMLSchema#string

Jyoti Harwalker

http://www.w3.org/2001/XMLSchema#string

Mohammed Orloff

http://www.w3.org/2001/XMLSchema#string

Roxanne E Steinle

http://www.w3.org/2001/XMLSchema#string

P2860

The Ki-67 protein: from the known and the unknown

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

mTOR and cancer: insights into a complex relationship

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity.

Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

P304

3062-3072

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2010.090872

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43159963

http://www.w3.org/2001/XMLSchema#string

P698

20395440

http://www.w3.org/2001/XMLSchema#string

P932

2877865

http://www.w3.org/2001/XMLSchema#string